Revvity is stepping onto one of cancer research’s biggest stages with a clear message: faster, smarter science is within reach.

 

At the AACR Annual Meeting 2026 in San Diego from April 17–22, the company will unveil a powerful lineup of research-use-only oncology tools aimed at transforming how scientists tackle cancer—from early discovery to translational breakthroughs.

 

The showcase centers on a fully integrated ecosystem designed to streamline the entire research pipeline. 

 

From sample preparation and assay development to advanced imaging, detection, and data analysis, Revvity is positioning its technologies as a connected engine for discovery. The added edge: AI-driven insights that promise faster, deeper understanding of complex biology while maintaining high data quality and reproducibility.

 

“Our focus is on empowering researchers with connected, end-to-end solutions that remove complexity and accelerate progress,” said Kevin Quick of the company. “At AACR, we’ll demonstrate how our technologies are helping advance cancer research and ultimately contribute to improved patient outcomes.”

 

Among the headline innovations: cutting-edge imaging systems for 3D and live-cell analysis, AI-powered software for in vivo data interpretation, high-sensitivity detection platforms, and automated tools designed to simplify sample preparation. The portfolio also includes next-generation reagents and genomics solutions built to boost consistency and precision across experiments.

 

Taken together, the rollout underscores Revvity’s broader strategy—linking instruments, software, reagents, and services into a seamless workflow. The goal is ambitious but clear: reduce variability, sharpen decision-making, and help researchers translate complex findings into real-world impact faster.

 

As cancer research grows increasingly data-heavy and multidisciplinary, Revvity is betting that integration—not just innovation—will define the next wave of breakthroughs.